Huntington Bank Director of Equity Research, Randy Hare, shares insights from their weekly "3 Things We Learned This Week" blog post in a video. He discusses the main factor influencing the International Monetary Fund's global GDP forecast, reviews the stock market's performance and leading sectors, and explains why falling oil prices haven't yet led to cheaper gas.

Canadian Natural Resources (CNQ) has outperformed the market over the past five years, achieving an average annual return of 24.08%. An investment of $100 in CNQ stock five years ago would now be worth $296.15, demonstrating the significant impact of compounded returns. The company currently has a market capitalization of $90.86 billion.

L3Harris Technologies secured a contract valued over $65 million to produce solid rocket motors for the Army Tactical Missile System (ATACMS). The ATACMS is a long-range guided missile utilized by the U.S. military and its allies. This contract highlights L3Harris's role in supplying critical components for defense systems.

Vertex Pharmaceuticals maintains a strong position in the cystic fibrosis (CF) treatment market with products like Trikafta, generating significant revenue. The company is strategically focused on expanding its pipeline beyond CF into areas like pain management (suzetrigine), diabetes, and gene editing to sustain growth amidst potential CF market saturation. Analysts largely view Vertex positively, citing its robust CF franchise and pipeline potential as key drivers for future upside, especially for investors in the US and English-speaking markets.

Google's 2026 Discover Core Update is changing how retail investors access information on AutoZone Inc. stock (US0533321024) via mobile devices, providing personalized content directly to their Google app feeds. This shift prioritizes proactive delivery of insights based on user activity, allowing for faster decision-making without traditional search queries. The update emphasizes high-quality, trustworthy content focused on financial utility, making it easier for investors to track key metrics and market trends for AutoZone.

Google's 2026 Discover Core Update is significantly changing how investors receive information on companies like Invesco Ltd. This update personalizes asset management trends, ETF flows, and AUM growth directly into users' Google app feeds. For retail investors tracking Invesco Ltd stock, this means faster access to tailored insights on key metrics and strategic initiatives without traditional search queries.

TD Cowen increased its price target for Celestica (NYSE:CLS) to $350.00 from $330.00, maintaining a "hold" rating even though the new target suggests a potential 10.9% downside. The consensus among analysts for Celestica is a "Moderate Buy" with an average target price of $369.11, though individual targets vary widely. Despite the positive analyst sentiment, company insiders have been net sellers, offloading shares worth approximately $88 million in the last 90 days.

Cosmos Health Inc. announced it will begin production of its Liv18 liver health supplement in April 2026, anticipating over $5 million in annual revenue and a 75% gross margin. The company has completed development and commercial setup ahead of schedule, with manufacturing occurring in U.S. GMP-certified facilities. This move is expected to significantly improve the company's gross profit margin and is supported by a direct-to-consumer sales strategy and planned advertising investments.

Globe Life Inc. (NYSE: GL) has reached an all-time high stock price of $152.79, reflecting a 30.21% increase over the past year. The company's strong performance is supported by a P/E ratio of 10.83 and a PEG ratio of 0.58, suggesting it is currently undervalued according to InvestingPro analysis. This achievement follows recent news of their Q4 2025 earnings report, a dividend increase, and new board member appointments, further solidifying investor confidence.

Wells Fargo has upgraded Biogen (BIIB) to Overweight with a $250 price target, citing confidence in its late-stage immunology and kidney pipeline programs as key medium-term growth drivers. This upgrade, along with another from Piper Sandler, signals increasing conviction that Biogen is successfully diversifying its revenue streams beyond its struggling Alzheimer's and MS franchises. The company's lower forward P/E ratio and recent acquisition of China rights for felzartamab further support the thesis of a credible transformation.